Urinary incontinence and related urogenital symptoms in elderly women.
The aims of this study were to investigate the prevalence of urinary incontinence (UI), urinary tract infections (UTI) and related urogenital symptoms (UGS) in a representative sample of elderly women (Papers I & II), and to investigate factors (Papers II & III) influencing the prevalence of UI in these women. The effects of treatment with oral estriol and placebo on the vaginal bacterial flora, vaginal cytology and urogenital symptoms in elderly women suffering from the urogenital estrogen deficiency syndrome were compared (Paper IV). A health care programme, based on an algorithm model, for the investigation and treatment of elderly women suffering from UI and related UGS, was designed and applied to a large group of elderly women (Paper V). The prevalence of UI increased in a linear fashion from 12% in the 1940 birth cohort to 25% in the 1900 birth cohort (Papers I & II). There was similar increase in the prevalence of UTI from 14% in the 1920 birth cohort to 23% in the 1900 birth cohort. In contrast, the reported prevalence of UGS such as vaginal discomfort, discharge and pruritus did not increase with age. The prevalence of UI increased with increasing parity and after hysterectomy, but was unaffected by the duration of previous oral contraceptive usage. There was no evidence to suggest that the prevalence of UI increased at the time of the last menstrual period. Neurological illnesses were an uncommon cause of UI in women < or = to 75 years of age (Paper III). Oral estriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks) had a positive influence on vaginal pH, cytology and the vaginal bacteria flora, and on UGS in elderly women suffering from the urogenital estrogen deficiency syndrome (Paper IV). Using objective techniques of evaluation (Paper V) it was possible to demonstrate successful treatment of elderly women with urge and mixed incontinence using a simple health care programme. There was however no evidence of improvement in women suffering from stress incontinence when using the same treatment regime. Women with all types of incontinence, treated according to this algorithm model, displayed an improvement in vaginal pH, vaginal cytology and the vaginal bacterial flora.
Molander
U
U
Continence Clinic, Vasa Hospital, Gothenburg, Sweden.
D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003276:Contraceptives, Oral / Q000009:adverse effects; D004311:Double-Blind Method; D004964:Estriol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004967:Estrogens / Q000172:deficiency; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008593:Menopause; D008875:Middle Aged; D009422:Nervous System Diseases / Q000150:complications; D009460:Neurologic Examination; D010298:Parity; D015995:Prevalence; D013548:Sweden / Q000453:epidemiology; D014549:Urinary Incontinence / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D014570:Urologic Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D014621:Vagina / Q000187:drug effects / Q000382:microbiology / Q000473:pathology
D003276:Contraceptives, Oral; D004967:Estrogens; D004964:Estriol